Methylphenidate: Difference between revisions
>MeyveliPasta m update citation - turkey legality |
>Shoe Expanded and updated the history and culture section, added missing citations and new information. |
||
Line 11: | Line 11: | ||
==History and culture== | ==History and culture== | ||
{{historyStub}} | {{historyStub}} | ||
The compound was first synthesized in 1944 by chemist Leandro Panizzon and marketed as “Ritalin” by Swiss company CIBA (now Novartis) in 1954. The name “Ritalin” derives from the first name of Panizzon’s wife, i.e. Marguerite, nicknamed Rita,<ref>https://pmc.ncbi.nlm.nih.gov/articles/PMC3000907/#Sec8</ref> who used Ritalin to compensate for low blood pressure.<ref>Richard L. Myers https://books.google.com/books?id=a4DuGVwyN6cC&q=named+ritalin+after+his+wife&pg=PA178 ABC-CLIO. p. 178. ISBN 978-0-313-33758-1.</ref> | |||
It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.<ref>{{cite journal | journal=The Pharmaceutical Journal | title=Narcotics monitoring board reports 66% increase in global consumption of methylphenidate | date= 2015 | url=http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article | issn=2053-6186 | doi=10.1211/PJ.2015.20068042}}</ref> In | Methylphenidate was not reported to be a stimulant until 1954.<ref>Heal DJ, Pierce DM (2006). "Methylphenidate and its isomers: their role in the treatment of attention-deficit hyperactivity disorder using a transdermal delivery system". ''CNS Drugs''. '''20''' (9): 713–738. doi:[https://link.springer.com/article/10.2165/00023210-200620090-00002 10.2165/00023210-200620090-00002]. [https://pubmed.ncbi.nlm.nih.gov/16953648/ PMID 16953648.] [https://www.semanticscholar.org/paper/Methylphenidate-and-its-Isomers-Heal-Pierce/b19872ac87ae24e3cd161a1719d192b9fccffa1b S2CID 39535277.]</ref> The drug was introduced for medical use in the United States in 1957.<ref>Wood S, Sage JR, Shuman T, Anagnostaras SG (2014). "Psychostimulants and cognition: A continuum of behavioral and cognitive activation". ''Pharmacol Rev''. '''66''' (1): 193–221. https://pmc.ncbi.nlm.nih.gov/articles/PMC3880463/</ref> Although it was first used to allay [[Barbiturates|barbiturate]]-induced coma, narcolepsy, and depression.<ref>Myers RL (August 2007). [https://archive.org/details/100mostimportant0000myer ''The 100 Most Important Chemical Compounds: A reference guide''.] ABC-CLIO. p. 178. [[ISBN (identifier)|ISBN]] [[Special:BookSources/978-0-313-33758-1|<bdi>978-0-313-33758-1</bdi>]].</ref> It was later used to treat memory deficits in the elderly.<ref>Stolerman I (2010). ''Encyclopedia of Psychopharmacology''. Berlin, DE / London, UK: Springer. p. 763. ISBN [[Special:BookSources/978-3-540-68698-9|<bdi>978-3-540-68698-9</bdi>]].</ref> Production and prescription only rose significantly in the 1990s, especially in the United States, as the ADHD diagnosis came to be better understood and more generally accepted within the medical and mental health communities.<ref>Woodworth T (16 May 2000). [https://web.archive.org/web/20071012061712/http://www.dea.gov/pubs/cngrtest/ct051600.htm DEA Congressional Testimony (Report)]. U.S. Drug Enforcement Administration. Archived from [https://www.dea.gov/pubs/cngrtest/ct051600.htm the original] on 12 October 2007. Retrieved 2 November 2007.</ref> | ||
In 2000, Alza Corporation received US FDA approval to market Concerta, an extended-release form of methylphenidate.<ref>[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1a88218c-5b18-4220-8f56-526de1a276cd "Concerta- methylphenidate hydrochloride tablet, extended release"]. ''DailyMed''. 1 July 2021.</ref><ref>[https://web.archive.org/web/20101216171133/http://centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637 "Newly Approved Drug Therapies (637) Concerta, Alza".] ''CenterWatch''. Archived from [https://www.centerwatch.com/drug-information/fda-approvals/drug-details.aspx?DrugID=637 the original] on 16 December 2010. Retrieved 30 April 2011.</ref> | |||
It was estimated that the number of doses of methylphenidate used globally in 2013 increased by 66% compared to 2012.<ref>{{cite journal | journal=The Pharmaceutical Journal | title=Narcotics monitoring board reports 66% increase in global consumption of methylphenidate | date= 2015 | url=http://www.pharmaceutical-journal.com/news-and-analysis/news-in-brief/narcotics-monitoring-board-reports-66-increase-in-global-consumption-of-methylphenidate/20068042.article | issn=2053-6186 | doi=10.1211/PJ.2015.20068042}}</ref> In 2022, it was the 32nd most commonly prescribed medication in the United States, with more than 17 million prescriptions.<ref>[https://clincalc.com/DrugStats/Drugs/Methylphenidate "Methylphenidate Drug Usage Statistics, United States, 2013 - 2022"]. ''ClinCalc''. Retrieved 30 August 2024.</ref> It is available as a generic medication.<ref>[https://www.drugs.com/monograph/methylphenidate.html "Methylphenidate Hydrochloride Monograph for Professionals".] ''Drugs.com''. AHFS. Archived from [https://web.archive.org/web/20181003194029/https://www.drugs.com/monograph/methylphenidate-hydrochloride.html the original] on 19 December 2018. Retrieved 19 December 2018.</ref> | |||
==Chemistry== | ==Chemistry== |